Clots, Capital, and Deal Activity in the Thrombectomy Devices Market

Thrombectomy is the focus this week, with two major announcements that could meaningfully move this space forward. One came from Inquis Medical, which announced a $75 million Series C round backed by an undisclosed strategic investor. The other came from Boston Scientific, which announced plans to acquire Penumbra for $14.5 billion, marking the largest acquisition in Boston Scientific’s history.

Together, these headlines point to a market where mechanical clot removal is gaining momentum across multiple indications. The thrombectomy devices market remains underpenetrated in several of its largest patient populations, which is helping drive both investment and M&A activity.

What Thrombectomy Means in Practice

Thrombectomy refers to the surgical removal of a thrombus, or blood clot. The procedure is a minimally invasive surgery that uses a catheter-based device to mechanically fragment, retrieve, or aspirate clot material to restore blood flow.

The procedure is often used when rapid reperfusion is critical, including:

  • Acute ischemic stroke
  • Venous thromboembolism, such as deep vein thrombosis (DVT) and pulmonary embolism (PE)
  • Peripheral arterial occlusions

In select cases, thrombectomy is also performed in coronary arteries to clear occluded vessels.

Inside the Market Opportunity

Thrombectomy is relevant across several thrombus-related conditions:

  • DVT is the most common, and while many DVT cases are managed medically, procedure volumes remain substantial. DVT represents roughly half of all peripheral thrombectomies performed, of which an estimated 100,000 thrombectomies were performed in the U.S. in 2025, according to internal estimates.
  • Ischemic stroke is the high-growth segment. U.S. ischemic stroke thrombectomy procedure volumes are expected to grow at a CAGR of 10.0% from 2025 to 2030. By volume, an estimated 50,300 ischemic stroke thrombectomy procedures were performed in the U.S. in 2025.
  • PE, while less common overall, is showing steep growth potential. Penumbra estimates the annual U.S. opportunity at approximately 160,000 patients. In the U.S., there are an estimated 900,000 symptomatic PE cases annually, with 15%–25% categorized as intermediate- to high-risk patients who may advance beyond anticoagulation and thrombolytic therapy. Penumbra estimates the addressable share may be closer to ~44% of PE cases in the U.S.
  • Peripheral arterial occlusion is less frequent than PE, with thrombectomy procedure volumes estimated in the low thousands annually in the U.S.

Inquis Medical’s Series C and the Strategic Investor Question

Inquis Medical is a privately held, commercial-stage company focused on PE intervention. Its flagship product, the AVENTUS™ Thrombectomy System, is intended for PE treatment and incorporates two differentiating features:

  • TrueClot™ Sensing technology, which uses Electrical Impedance Spectroscopy at the catheter tip to distinguish between clot, blood, and vessel wall.
  • Integrated filtration, which separates clot material and allows filtered blood to be reinfused into the patient.

The Series C financing is intended to help Inquis scale commercial operations following FDA 510(k) clearance for AVENTUS in June 2025.

This blog is originally published here: https://www.lifesciencemarketresearch.com/insights/clots-capital-and-deal-activity-in-the-thrombectomy-devices-market

Comments

Post a Comment

Popular posts from this blog

Cover Story: A Page from Ray Cohen’s Playbook: Scaling, Exiting, and Winning in Medtech

With four decades of company-building, IPOs, boardroom leadership, and monumental exits behind him, Raymond W. Cohen has become one of medtech’s most successful operators. But behind the financial wins — including the recent back-to-back $3.7 billion Axonics and $600 million SoniVie acquisitions by Boston Scientific — is a deeper story of Cohen’s contrarian, full-transparency, people-centered, no-BS approach to leadership and strategy. “People crave inspired, authentic, and transparent leadership that thinks big and acts boldly. They want to be enrolled in a vision of what is possible, and be recognized and compensated for creating measurable results, not be fed a bunch of platitudes.” A quote that is classic  Ray Cohen  — blunt, unapologetic, no-nonsense, and grounded in hard-won experience. With more than four decades in medtech, Cohen has done what many aspire to — build, lead, scale, and sell high-stakes, successful ventures with precision and zero fluff. Known for his no-...
Read more

The Weekly Recap 6/13/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure over $63M in new funds, receive FDA 510(k) clearances, announce an acquisition, and much more as we wind down   LSI Asia  ’25 in Singapore and gear up for  LSI Europe  ’25 in London (September 7–11). Accelus Received FDA 510(k) clearance for the FlareHawk Interbody Fusion System to be safely subjected to MRI scanning in certain conditions. The clearance supports Accelus’s commitment to safe, high-performance spinal solutions and expands imaging options for patients with FlareHawk implants. Aortyx Raised $16M to advance its bioresorbable aortic patch toward first-in-human trials. The funding supports continued development of Aortyx’s minimally invasive, tissue-regenerating solution for aortic dissection and positions the company for clinical entry within two years. Atraverse Medical Closed $29.4M in follow-on financing to scale U.S. commercialization of HOTW...
Read more

Medtech in 2025: Key Insights from Q1 Earnings

  As we venture into Q2 of 2025, the medtech industry continues to navigate challenges while remaining on a positive growth trajectory. The early earnings reports from major medtech companies provide valuable insights into how the sector is performing and where it is heading. Despite the pressures of ongoing macroeconomic uncertainty, the first quarter of 2025 shows a sector that’s resilient, with many companies reporting strong growth across their key divisions. For more information visit here:  https://www.slideshare.net/slideshow/medtech-in-2025-key-insights-from-q1-earnings/279045324
Read more